Key points from article :
President at Icaria Life Sciences presented at Ending Age-Related Diseases 2019.
Part of Ichor Therapeutics, also providing contract research organisation (CRO) services.
Small molecule drug discovery follows standard steps including high throughput screening, lead optimisation and clinical candidate selection.
Icaria uses RP-Tag to improve production of functional proteins.
Have to develop and validate cell models as often can’t reproduce published research.
Does compound only work in humans?
Need to validate target model proteins.
Indications are very clear with traditional drug discovery.
But in ageing research the indications are complex
Should you take a systemic or localised approach?
